Noetic Fund
Noetic Fund is a global investment firm focused on building emerging technologies in molecular therapeutics, digital health, medical devices, and wellness, with a particular emphasis on mental health, pain, and central nervous system-related complications. The firm is committed to nurturing scientific advancements in mental, emotional, and physiological health by investing in innovative therapies and modalities that optimize the human experience. Noetic Fund aims to develop sustainable, safe, and accessible solutions to improve the mental health landscape for current and future generations.
Noetic Fund
87 Scollard Street, Second Floor, Toronto, ON, M5R 1G4 Canada
Portfolio
Improves body’s resilience to stress, aiding focus, sleep, and energy.
#Wellness Technology
Develops psychedelic compounds for neurological and psychiatric disorders.
#Pharmaceuticals
Developing new ketamine therapies for large-market and orphan indications.
#Biotechnology
Accelerates patient access to evidence-based innovation in mental health. Exited.
#Mental Health Care
Utilizes proprietary drug discovery platforms for psychiatric disorders. Exited.
#Psychedelic Therapeutics
Developing non-hallucinogenic treatments based on psychedelic compounds.
#Pharmaceuticals
Focuses on serotonin 2A receptor agonists, commonly known as psychedelics. Exited.
#Pharmaceuticals
Develops novel medicines harnessing the therapeutic promise of psychedelics.
#Pharmaceuticals
Develops psychedelic inspired medicines for addiction and mental illness. Exited.
#Biotechnology
Accelerates evidence generation and knowledge about psychedelic and alternative medicines.
#Clinical Research
Develops biosynthetic psychoactive compounds for mental health issues.
#Pharmaceuticals
Transforms lives of patients with neurological and psychiatric disorders.
#Biotechnology
Focuses on fungi and plant medicine with clinical immersions and supplements.
#Health and Wellness
Creates and supports early-stage psychedelic and wellness companies.
#Psychedelic and Wellness
Treats and prevents cognitive deficits across brain disorders and aging.
#Pharmaceuticals
Dedicated to extending the work of Dr. Shulgin in psychedelic drug discovery.
#Psychedelic Drug Discovery
Key People
Managing Partner